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Antibiotic resistance (ABR) is a critical threat to public health 
globally that, if unchecked, could result in 10 million deaths per 
year at a cumulative cost of USD100 trillion by 2050.[1] Overuse and 
misuse of antibiotics has resulted in the emergence of multidrug-
resistant (MDR), extensively drug-resistant (XDR) and pan-drug-
resistant (PDR) bacteria, which are increasingly common in South 
Africa (SA).[2] To alleviate the crisis, antibiotic stewardship (AS) has 
emerged as a concept that embodies the appropriate use of antibiotics 
with the goal of optimising patient outcomes while reducing the 
emergence of resistant bacteria.[3]
The majority (75 - 80%) of antibiotics for systemic use in adults 
and children are prescribed in the community, with acute respiratory 
tract infections (ARTIs) such as bronchitis, pharyngitis and sinusitis 
the most common indications.[4-7] Although most ARTIs are of viral 
origin and are self-limiting, so non-antibiotic treatment options 
should be preferred, they still account for most of the antibiotics 
prescribed in primary healthcare. It is estimated that almost 60% of 
patients with an ARTI receive an unnecessary antibiotic, which is 
unlikely to be of benefit.[5,6,8-10]
The reasons for the excessive prescription of antibiotics in the 
community are complex and include the lack of a precise diagnosis 
of the cause of the presenting respiratory illness, perceived patient 
and parental preference for the receipt of an antibiotic, and a lack 
of appreciation of the negative impact of unnecessary prescriptions, 
particularly with regard to the development of resistance in the 
community. Fear of litigation, both consciously and unconsciously, 
may also be a factor. Perhaps equally important are constraints 
on the time available to perform a full clinical assessment and 
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excessive antibiotic prescribing to patients can reduce resistance and improve microbiological and clinical outcomes. Therefore, although 
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are multifactorial but, perhaps most importantly, the overlapping clinical features of viral and bacterial infections dramatically reduce 
the ability of GPs to distinguish which patients would benefit from an antibiotic or not. As a consequence, the need for tools to reduce 
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the considerable diagnostic uncertainty 
that arises as a consequence of overlapping 
clinical features between bacterial and 
viral infections and even non-infectious 
respiratory illnesses.[10,11]
This problem is exacerbated in community 
practice by the lack of availability of 
sensitive, specific and cost-effective tests to 
distinguish viral from bacterial infections. 
Even the presence of bacteria at the site of 
a suspected infection does not necessarily 
identify whether it is bacterial or not, as 
without evidence of inflammation it probably 
represents colonisation or contamination.[12,13] 
This implies that a good clinical history and 
examination alone may not be sufficient, 
and the judicious use of biomarkers, such as 
point-of-care testing (POCT) for C-reactive 
protein (CRP), may aid in diagnosis and thus 
reduce antibiotic consumption.[11]
The purpose of this review is to provide 
a simple framework for clinical decision-
making regarding antibiotic use and, where 
applicable, the appropriate use of laboratory 
tests for common ARTI syndromes in pri-
mary practice. This ‘diagnostic stewardship’ 
should be a key component of AS, providing 
assistance to clinicians in everyday practice 
to differentiate bacterial from viral infect-
ions or non-infectious conditions and, in 
so doing, boosting confidence in decision-
making. Conceptually, this review should be 
understood as one strategy within a multi-
modal primary care AS programme with 
the ultimate aim of reducing redundant 
antibiotic use (Fig. 1).[14]
Patients presenting with 
acute cough
Acute cough, defined as lasting <3 weeks 
(and without more worrying features such as 
haemoptysis, weight loss or other symptoms 
of tuberculosis, chest pain or a history of 
aspiration) is estimated to represent the most 
common cause for consultation with a general 
practitioner (GP) and one of the commonest 
reasons for prescription of antibiotics in 
community practice; in one study, 52.7% of 
adult patients presenting with acute cough 
received an antibiotic.[15] This is despite Whaley 
et al.[16] having recently demonstrated that the 
most common infective causes of acute cough 
were viral: the common cold, nonspecific upper 
respiratory tract infections (URTIs) and acute 
bronchitis, for which antibiotic therapy is not 
indicated. Non-infectious conditions causing 
cough include postnasal drip from allergic 
rhinitis, gastro-oesophageal reflux, smoking, 
angiotensin-converting enzyme inhibitors and 
undiagnosed asthma. The symptoms of an 
acute cough can take up to 3 weeks to settle, 
and it is this prolonged duration that often 
precipitates the initial antibiotic prescription 
(and possibly even a second one), out of 
desperation either on the part of the patient or 
the doctor.[17]
The common cold
It should be understood that the clear nasal 
secretions character istic of the common 
cold frequently become purulent without 
signi fying superimposed bacterial infection 
(Fig. 2). This is a common misperception 
and hence, even with coughing, which is a 
normal accompaniment of a postnasal drip, 
antibiotics are not required.[8] Patients should 
be advised that the average duration of the 
illness (before and after seeing the doctor) is in 
the region of 10 - 11 days. [17] Obtaining nasal 
swabs for culture is strongly discouraged even 
if the cough is persistent, and is particularly 
wasteful in resource-challenged low- and 
middle-income countries.
Only symptomatic treatment should be 
provided, which may include analgesics such 
as paracetamol (for relief of fever, headache or 
sinus discomfort). Aspirin should be avoided 
in children <18 years of age because of the 
risk of Reye’s syndrome. In those ≥12 years of 
age, oral or topical decongestants may relieve 
rhinorrhoea and nasal congestion; however, 
these should not be used for >5 days as longer 
durations may lead to rebound congestion 
known as rhinitis medicamentosa. Early use 
of a nasal steroid may reduce the duration of 
the postnasal drip-induced cough.
Acute bronchitis
Clinically, it can be difficult to differentiate 
acute bronchitis from other conditions 
that may present with cough.[18] The major 
differen tial diagnosis is community-acquired 
pneumonia (CAP), which does require 
antibiotics (Fig. 3). However, the presentation 
is very similar to that of the common cold.[19] 
The latter is usually associated with nasal 
congestion and rhinorrhoea and typically 
lasts only 7 - 10 days, but it is important to 
recognise that bronchitis also seldom occurs 
in isolation as it frequently results from a 
‘sinobronchitis’ occurring as a consequence 
of a virally induced postnasal drip. The 
Healthy person
Transmission of virusSusceptible to infections
Vaccination Exercise
Complementary and
alternative medicine
(e.g. probiotics)
Physical barriers
(e.g. hand washing)
Person with symptoms of a respiratory infection
Need for reassurance Expectations of antibiotics Symptom relief
Steroids
Public campaigns
Complementary
and alternative
medicine (e.g. zinc)
Over-the-
counter
medicine
(e.g. non-steroidal
anti-inammatory
drugs)
GP
education
Patient consulting a GP
GP prescribing
habits
Perceived
patient demand
Patient
expectations
Diagnostic uncertainty
Shared
decision-
makingSafety
netting Therapeutic
vacuum
Time pressure
Behavioural
intentions
Shared decision-
making
Diagnostic
tests and
biomarkers
Delayed antibiotic
prescribing Policy
Complementary
and alternative
medicine
(e.g. Echinacea)Patient prescribed antibiotics
Mismatch between guidelines and packet size
Person with redundant antibiotics
Policy
Fig. 1. Overview of strategies to minimise antibiotic use in primary care at each stage of the path from 
healthy person to antibiotic prescription (reproduced with permission from Hansen et al.[14]).
Nasal stuness and throat irritation
•  Low-grade fever
•  Malaise
•  Myalgia
Coughing+/– +/–
•  Sneezing
•  Watery nasal discharge
Mucopurulent secretions* 1 - 3 days
Persists up to 10 days in 31% of cases Persists up to 10 days in 35% of cases
*Obtaining nasal swabs for culture is strongly discouraged. 
Fig. 2. Natural history of the common cold.[8] 
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presence of discoloured sputum should also 
not be used as an indicator of bacterial as 
opposed to viral infection, as both of these, 
and also non-infectious conditions such as 
asthma, frequently present with purulent or 
purulent-looking sputum.[18]
In most cases, history and physical exami-
nation are sufficient to identify more serious 
conditions requiring chest radiography 
(CXR). Only in select circumstances may 
additional diagnostic testing be required. If 
it is suspected that an outbreak of bronchitis 
may be due to Mycoplasma pneumoniae or 
Chlamydophila pneumoniae, especially when 
presenting in young adults, a specimen for 
molecular confirmation may be warranted. A 
swab for Bordetella pertussis polymerase chain 
reaction (PCR) is warranted in unvaccinated 
patients with a paroxysmal or ‘whooping’ 
cough.[18]
Data are limited regarding the management 
of acute bronchitis in children. Most would 
regard it as an extension of a nonspecific 
viral URTI and no laboratory testing 
would be advised. Microscopy, culture and 
sensitivity (MC&S) on sputum specimens 
is strongly discouraged, as antibiotics may 
inappropriately be prescribed for growth of 
colonisers or normal flora. Perhaps the most 
important feature of a more severe condition 
requiring a CXR is tachypnoea.
Antibiotics do not alter the natural 
course of acute bronchitis and should not 
be prescribed unless comorbid risk factors 
are present [18] (Fig. 3). Despite most cases 
being viral in origin, doctors in the USA 
continue to prescribe antibiotics to adults 
with this diagnosis despite clear-cut guideline 
recommendations to the contrary.[16] In fact, 
despite significant interventions, including 
guidelines, quality measures and more than 
15  years of educational effort by the Centers 
for Disease Control and Prevention (CDC), the 
antibiotic prescribing rates for acute bronchitis, 
which should be zero, have remained at 71% 
and even increased between 2006 and 2010.[20]
Management should include advice to 
the patient as to the benign nature and 
course of the condition, with the potential 
for symptom resolution to take up to 
3  weeks, together with a nasal steroid and 
with instructions for the patient to return 
should symptoms fail to resolve or if pyrexia, 
pleuritic chest pain or haemoptysis develop. 
A macrolide antibiotic should be prescribed 
for confirmed B. pertussis infections and, 
although it has limited symptomatic effect, it 
does reduce the risk of transmission.
Acute pharyngo­
tonsillitis
Respiratory viruses are the most common 
causes of acute pharyngitis/tonsillitis, while 
group A β-haemolytic streptococci (GABHS) 
(Streptococcus pyogenes) is the most impor-
tant bacterial pathogen; these account for 
15% and 40% of adult and paediatric cases, 
respectively.[21,22] It is important to note that 
asymptomatic carriage of GABHS occurs in 
up to 20% of children and in up to 5% of 
adolescents and young adults.[23]
Certain clinical features may assist in 
distinguishing viruses from GABHS (Fig. 4), 
and several clinical prediction rules to 
diagnose GABHS have been published.[24] 
However, reliance on these rules alone may 
still lead to antibiotic overprescription.[25] 
Currently, rapid antigen testing (RADT) 
methods have not been validated in SA 
and are therefore not routinely available. 
In a recent meta-analysis, the accuracy of 
RADT in children with pharyngitis selected 
as likely to have GABHS by means of clinical 
prediction rules, ranged from 24% (95% 
confidence interval (CI) 21 - 27) to 86% (95% 
CI 84 - 89).[25] According to the authors, none 
of 16 RADTs tested had good correlation 
with the diagnosis of GABHS by culture, 
particularly as the disease spectrum, the size 
of the bacterial inoculum and the skill of 
the operator all affect test performance.[25,26] 
Molecular methods, including PCR, offer 
the highest accuracy for GABHS detection 
(approaching 95 - 100%), but widespread use 
is limited by limited resources.[25]
CRP POCT does not distinguish between 
those who do or do not require antibiotic 
therapy.[27] In addition, CRP values of 10 - 
60 mg/L measured in the laboratory may not 
be able to distinguish between viral and bac-
terial pathogens in patients with symptoms of 
<7 days’ duration.[28] Although measurement 
Patients presenting with acute cough and/or other LRTI symptoms
Diagnostic uncertainty
CAP >100 20  - 100 <20 Acute bronchitis
POCT CRP (mg/L)
Severity assessment
Inpatient
antibiotic
treatment
Outpatient
antibiotic
treatment
Routine
sputum and
CXR not
indicated
• No further laboratory investigations indicated
• Symptomatic treatment
• No antibiotic prescribed unless exception criteria met*
• No antibiotic prescribed unless:
   · Risk factors present for a complicated course†
   · Patient deteriorates clinically
• Alternatively, provide delayed antibiotic script if follow-up
  possible
Clinical examination
The following features favour CAP over acute bronchitis:
Where there is diagnostic uncertainty, follow the CRP algorithm
• Fever ≥38°C
• Tachypnoea ≥24/min
• Tachycardia ≥100/min
• Evidence of consolidation on examination:
·  Crackles
·  Bronchial breathing
·  Increased tactile fremitus or vocal resonance
*For patients with acute cough >80 years with one or more, or >65 years with two or more, of the following features, the no-
  antibiotic prescribing strategy and the delayed-antibiotic prescribing strategy should not be considered:[17] 
•  Hospitalisation in the past year
•  Current use of oral steroids or other immunosuppressive drugs
•  HIV/AIDS
•  Type 1 or type 2 diabetes mellitus
•  History of congestive heart failure.
†Risk factors:[45] 
•  Patients <3 months or >75 years
•  Comorbid conditions:
    · Heart failure
   · Diabetes mellitus
   · COPD
   · Asthma
   · Immunocompromised.
Fig. 3. The use of POCT CRP measurement to distinguish CAP from acute bronchitis in the primary 
care setting.
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of the absolute neutrophil count may increase 
diagnostic accuracy for GABHS when rapid 
antigen testing is not avail able, routine use 
is also not recommended;[29] nor are anti-
streptococcal antibody titres, as they reflect 
past and not current infections. [30] Taking all 
these factors into account, the diagnostic and 
antibiotic treatment criteria are summarised 
in Fig. 4. Correctly per formed throat cultures 
are still considered the gold standard for the 
diagnosis of acute GABHS pharyngotonsil-
litis, with a high sensitivity of 90 - 95%.[30] 
To achieve this, it is recommended that the 
tonsils and posterior pharyngeal wall be vig-
orously swabbed.[21]
It is important to note that a delay in 
antibiotic prescription pending availability 
of culture results does not reduce efficacy in 
the prevention of acute rheumatic fever and, 
as such, a delayed antibiotic prescription 
strategy is advised for all patients where 
a throat swab has been sent for MC&S. 
However, throat swabs for confirmation 
of GABHS may not be feasible in many 
SA settings owing to increased direct and 
indirect financial costs and the need for 
additional healthcare visits. In such cases, 
empirical antibiotic therapy is advised for 
all patients aged 3 - 21 years who fit the 
clinical prediction rules. Generally speaking, 
the mainstay of the management of acute 
pharyngitis is symptomatic and includes 
adequate analgesia and antipyretics.
Acute otitis media
Correct clinical diagnosis of acute otitis 
media (AOM) is the key to reducing overall 
antibiotic prescribing for this very common 
condition. Approximately 75% of children 
have had at least one episode by 3 years 
of age.[8] Time and clinical acumen is 
required to visualise the eardrum. Symp-
tom presentation varies with age and, 
because typical symptoms overlap with 
other conditions, a clinical history alone 
is insufficient to predict whether AOM is 
present or not. To confirm the diagnosis, 
inflammation of the eardrum and a middle 
ear effusion, i.e. fullness, bulging, cloudiness 
and redness of the tympanic membrane 
(TM), must be identified (Fig. 5).
Although redness of the TM is an early 
sign of otitis media, it is not diagnostic on 
its own as there are numerous other causes, 
including crying, otitis externa, myringitis 
and barotrauma.[8] As a consequence, AOM is 
frequently mis- or overdiagnosed. Although 
clear visualisation of the TM is difficult 
at times, and because AOM is typically 
self-limiting, a high degree of diagnostic 
certainty is essential to minimise antibiotic 
overuse. Previous studies have shown that 
Diagnose acute otitis media when rapid onset of signs and symptoms of inammation
in the middle ear is present:
•  Otalgia
•  Irritability
•  Otorrhoea*
•  Fever
Symptoms include:
Enhance judicious antibiotic use by categorising:
•  Severity
•  Laterality
•  Age
•  Have non-severe disease
•  Have unilateral ear involvment
•  Age ≥2 years
Patients who:Patients with:
•  Symptomatic treatment
•  Provide immediate antibiotic
   script as such patients are more
   likely to benefit
•  Symptomatic treatment
•  Provide delayed antibiotic script
   ·  If follow-up possible, observation
   ·  Watchful waiting for 48 hours
•  More severe symptoms
   ·  Severe otalgia
   ·  Otalgia for >48 hours
   ·  Temperature ≥39°C
•  Bilateral involvement
•  Age ≤2 years
•  Bulging +/–
•  Erythema +/–
•  Oedema +/–
•  Immobility of the TM on visualisation
Signs include:
*Obtaining swabs and/or aspirations of otorrhoea (clear or purulent secretions) from a fresh tympanic perforation that is
  neither chronic nor recurring, in patients without prior exposure to antibiotics, is not routinely advised. 
Fig. 5. Diagnostic and treatment criteria for acute otitis media.
Diagnose all-cause pharyngotonsillitis when the following are present:
•  Sore throat
•  Fever
•  Dysphagia
•  Halitosis
•  Coryza
•  Cough
•  Conjunctivitis
•  Hoarseness
•  Anterior stomatitis
•  Discrete ulcerative lesions
•  Diarrhoea
Viral features Bacterial features
•  Tender anterior cervical lymphadenopathy
•  Pharyngeal erythema
•  Pharyngeal oedema or exudate
GABHS unlikely
GABHS more likely
Perform throat swab No throat swab•  Symptomatic treatment only
•  No antibiotic prescribed
•  Symptomatic treatment
•  Provide delayed antibiotic script
If GABHS grown, contact patient to have
antibiotic dispensed
•  Symptomatic treatment
•  Provide antibiotic script only if
   3 - 21 years old
Fig. 4. Diagnostic and treatment criteria for acute pharyngotonsillitis.
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with correct diagnosis unnecessary anti-
biotic use can be reduced by up to 66%. [31] 
Pneumotoscopy and tympanometry are 
very useful in determining the presence of 
a middle ear effusion. Routine tympano-
centesis on children with uncomplicated 
otitis is not feasible because of ethical and 
resource-related considerations. Swabs and/
or aspira tions of otorrhoea (clear or purulent 
secretions) that are neither recurring nor 
chronic, from a fresh tympanic perforation 
in patients without prior exposure to anti-
biotics, are also not routinely advised. 
However, with cases of AOM that closely 
follow swimming in children with perfor-
ations or grommets, an MC&S is very useful 
in excluding Pseudomonas aeruginosa that 
might be critical. Of note, CRP is unhelpful 
in determining whether antibacterial therapy 
can be withheld.
As AOM is often viral in aetiology (50% 
of cases) and with most bacterial cases 
(commonly S. pneumoniae, Haemophilus 
influenzae) resolving spontaneously, treatment 
of pain is the most critical aspect of the 
management of AOM. Antibiotics may be 
deferred for 48 hours in children ≥2 years of 
age while symptomatic therapy is administered 
(particularly where good follow-up is possible) 
if there is unilateral involvement and if the 
disease is not severe[8,32] (Fig. 5). Antibiotic 
prophylaxis in recurrent cases is of no value.
Acute bacterial 
rhinosinusitis
Acute bacterial rhinosinusitis (ABRS) is 
usually preceded by a viral URTI (Fig. 6). 
Allergy, trauma, dental infection or other 
factors that cause inflammation of the nose 
and paranasal sinuses may also predispose 
individuals to ABRS.[8] A raised CRP has 
been suggested as a potential discriminator 
between coryza and sinusitis, but absolute 
values have not been validated.[11]
Attempts to establish an aetiological diag-
nosis of sinusitis are typically reserved for 
patients who have not responded to convent-
ional medical treatment within 48 - 72 
hours, immunocompromised patients and 
those with complications. Sinus puncture 
and aspiration are the reference standard 
for a bacteriological diagnosis of ABRS. As 
most studies have shown poor correlation 
between nose and throat cultures and maxil-
lary sinus aspirates, nasal or nasopharyngeal 
swabs are not recommended; neither is the 
use of X-rays, which is strongly discouraged.
A recent meta-analysis of treatment out-
comes for ABRS has shown marginal benefit 
of antibiotics over placebo.[33] Overall, the 
number needed to treat for one adult to 
benefit is 13 (95% CI 9 - 22). Neither topical 
nor oral decongestants and/or antihistamines 
are recommended as adjunctive treatment, 
whereas both intranasal irrigation with 
either physiological or hypertonic saline and 
intranasal corticosteroids are recommended, 
the latter primarily in patients with allergic 
rhinitis.
Influenza
Influenza epidemics occur every year in 
SA during winter, typically from April to 
September, and should be considered in the 
differential diagnosis during this period. 
The clinical presentation varies from 
asymptomatic to severe and life-threatening 
infections. Typical and atypical presentations 
are depicted in Fig. 7.[34] The clinical diagnosis 
of influenza is often difficult and unreliable 
and, where indicated, laboratory testing 
should be performed.[35] Situations where this 
is necessary include where there is a cluster of 
cases in institutions such as nursing homes, 
or in severe illness, where neuraminidase 
inhibitors (such as oseltamivir) are indicated. 
The latter appears to provide only marginal 
benefit in the non-hospitalised (in contrast 
to the hospitalised) patient in the community 
and is not recommended outside of highly 
immunocompromised patients or those 
with severe chronic respiratory, cardiac or 
neurological conditions.[36] The laboratory 
test of choice is a respiratory tract PCR on 
•  Symptomatic treatment only
•  No antibiotics prescribed
•  Anterior or postnasal discharge*
•  Nasal obstruction
Diagnose all-cause rhinosinusitis when the following are present:
•  Symptoms <10 days
•  Non-severe symptoms
•  No ‘second sickening’ occurred
One of either:
With or without:
•  Facial pain/pressure
•  Change in sense of smell
Diagnose acute viral rhinosinusitis
(often associated with the common cold): •  Symptoms >10 days and <3 months
•  Severe long-lasting purulence or fever
•  Worsening of above symptoms (’second
   sickening’) occurs in <10 days
Diagnose acute viral rhinosinusitis:
•  Symptomatic treatment
•  Provide antibiotic script
*Obtaining nose or throat swabs for culture is strongly discouraged. 
Fig. 6. Diagnostic and treatment criteria for acute bacterial rhinosinusitis.
Diagnosis of inuenza
Acute onset characterised by: 
•  High fever
•  Headache
•  Myalgia
•  Dry cough
•  Nausea
•  Vomiting
•  Diarrhoea
•  Confusion
•  Drowsiness
Atypical presentation in children may include: In the elderly, inuenza may present as:
Laboratory testing is only indicated for those for whom specic antiviral therapy (e.g. oseltamivir)
is recommended, namely:  
•  Those with severe or complicated infection
•  Institutionalised patients
•  Those at high risk of developing severe or complicated infections
•  On a nasopharyngeal swab
•  Alternatively, on a throat or nasal swab
The laboratory test of choice is inuenza PCR: High-risk patients include:
•  Pregnant women
•  Age ≥65 years
•  Age ≤2 years
•  Chronic respiratory disease
•  Signicant cardiovascular disease
•  Chronic renal or hepatic disease
•  Obesity
•  Diabetes melltus
•  Immunosuppression, including HIV infection
•  Asthma
Fig. 7. Diagnostic and treatment criteria for influenza.
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a nasopharyngeal swab. Rapid tests are not 
recommended, as their sensitivity is often 
low and negative results do not exclude the 
diagnosis.[37]
Acute exacerbations 
of chronic obstructive 
pulmonary disease
With regard to chronic obstructive pulmonary 
disease (COPD), there are two situations in 
which antibiotics may be used. The first is 
for the treatment of acute exacerbations of 
COPD (AECOPD), which is the focus of this 
section. The second is long-term antibiotic 
use for COPD patients who continue to 
have recurrent exacerbations despite optimal 
COPD treatment; description of this is 
beyond the scope of this article.
For AECOPD, antibiotics are not always 
required and there is still uncertainty as to 
which patients would benefit most from 
antibiotic use. Up to 60% of AECOPD is said 
to be due to airway infection, but not all of 
these are bacterial, and viral infections play a 
significant role.[38] In general terms, however, 
antibiotic use appears to be of more value in 
patients with more severe COPD and in those 
with more severe exacerbations of COPD. 
Severity of AECOPD is usually classified 
using the Anthonisen criteria.[39] Type 1 
exacerbations, which are considered to be 
severe, have all three cardinal symptoms: 
increasing dyspnoea, increasing sputum 
volume and sputum purulence, while type 
2 exacerbations (moderate exacerbations) 
have two of those three symptoms and 
type 3 exacerbations have one of the 
symptoms together with one other symptom 
such as URTI, fever, wheeze, cough, or 
increased respiratory or heart rate.[39] The 
recommendations for routine antibiotic use 
in non-hospitalised patients and CRP testing 
are summarised in Fig. 8.[40-42]
Community­acquired 
pneumonia
Most definitions of CAP include symptoms 
of an LRTI (produc tive cough, pleuritic 
pain and dyspnoea) and focal chest 
signs (dullness to percussion, bronchial 
breathing and crackles), as well as systemic 
features such as tachypnoea, tachycardia and 
a temperature of ≥38°C. [43] These features 
are, however, nonspecific and can be present 
in other infections, such as acute bronchitis, 
acute sinusitis and non-infectious conditions, 
although tachypnoea and tachycardia are 
uncommon. Symptoms and signs are also 
often less pronounced in elderly patients.[44] 
If there is doubt as to the diagnosis,[45] POCT 
of CRP may be helpful and is discussed 
below and depicted in Fig. 3.
Routine CXR is not always available in 
primary care. If readily available, an X-ray is 
recommended if the signs and symptoms of 
CAP, as described above, are present or the 
POCT CRP is >100 mg/L, and if the diagnosis 
is uncertain. The former is useful to exclude 
conditions other than pneumonia such as 
empyema, lung abscess and bronchiectasis. 
Owing to low sensitivity, routine microbio-
logical tests such as Gram staining, sputum or 
blood cultures are also not indicated for the 
management of outpatients with low-severity 
CAP. [43,46,47] In children, urinary pneumococcal 
antigen testing is not recommended for the 
diagnosis of pneumococcal pneumonia owing 
to a high rate of false-positive results.[46]
Outpatient v. inpatient management: 
Severity assessment
In adults, once a clinical diagnosis of CAP has 
been made the primary care doctor should 
establish the optimal site for therapy (out-
patient or inpatient) using clinical judgement 
together with a severity-of-illness score such 
as the CURB-65 or CRB-65. [17,48] According 
to Bradley et al,[46] severity assess ment for 
children aged ≥3 - 6 months should also be 
performed on the grounds of the presence or 
absence of major and minor risk factors, but 
this is complex and may require referral.[49]
The role of biomarkers 
in differentiating types 
of ARTI
There is increasing evidence of a role for 
biomarkers, such as CRP and procalcitonin 
(PCT), in the management of patients 
presenting with ARTI.[45] In fact, a recent 
Cochrane review concluded that POCT for 
biomarkers (e.g. CRP) to guide antibiotic 
treatment of ARTIs in primary care can 
reduce antibiotic use and be used as an 
adjunct to a doctor’s clinical examination; 
this reduction in antibiotic use did not 
affect patient-reported outcomes, including 
recovery from and duration of illness.[45,50]
PCT is produced primarily by the C cells of 
the thyroid gland. Markedly raised levels are 
seen with bacterial infections and only minimal 
increases are reported with viral infections, 
which, through the stimulation of interferon-
gamma, inhibit PCT release. Conditions such 
as asthma or allergic rhinitis also do not result 
in PCT release. However, PCT lacks accu racy 
in less severely ill patients with ARTI seen 
in primary care[51] and does not perform any 
better than a POCT CRP measurement in 
this setting.[45] Because the negative predictive 
value for exclusion of bacterial infection is 
enhanced only by serial measurements and 
by concomitant negative cultures, and because 
rapid PCT testing on uncentrifuged venous 
blood is not readily available, this test is 
currently unlikely to influence management of 
RTI in primary care.[51,52]
In contrast, where there is diagnostic 
uncertainty, measurement of CRP levels can 
assist the physician in the management of 
patients presenting with features of ARTI. 
Recommendations for the use of CRP are 
based on reports from two large research 
groups: the IMPAC3T programme and the 
COPD patients presenting with the following cardinal symptoms: 
•  Increased dyspnoea
•  Increased sputum volume
•  Increased sputum purulence
<40 >40
Symptomatic treatment only
No antibiotic recommended
All 3 symptoms 
(type 1 exacerbation*) 
2/3 symptoms with one being
increased sputum purulence
(type 2 exacerbation*) 
2/3 symptoms without
increased sputum purulence
(type 2 exacerbation*) 
1/3 symptoms together with
one other symptom such as: 
•  An URTI in previous
   5 days
•  Increased wheezing
•  Increased coughing
•  Fever without
   obvious source
•  20% increase in
   respiratory or heart
   rate above baseline
(type 3 exacerbation*) 
Symptomatic treatment
Provide antibiotic script 
Symptomatic treatment
Provide antibiotic script 
Symptomatic treatment
Provide antibiotic script 
CRP POCT (mg/L)
*Anthonisen classication.
Fig. 8. Recommendations for antibiotic use in non-hospitalised patients with AECOPD.[40-42]
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GRACE consortium study. These studies, incorporated into the 2014 
NICE guidelines,[53] are very useful in providing evidence to support 
the clinician who is uncertain as to whether to include antibiotics in 
the management of LRTI or not.[45]
Based on POCT CRP level measurement, the following is 
recommended (Fig. 3):
• CRP <20 mg/L: CAP is unlikely, and antibiotic therapy is not 
routinely indicated
• CRP 20 - 100 mg/L: A watchful waiting approach is recommended, 
where antibiotic prescription is provided only if the clinical 
condition deteriorates and if comorbid risk factors are present. 
These would include age <3 months or >75 years; in children, 
cardiovascular and pulmonary conditions (except asthma); 
and in adults, heart failure, severe COPD, diabetes mellitus 
(especially with use of insulin), neurological conditions, severe 
renal insufficiency or immune compromise
• CRP >100 mg/L: CAP is more likely, and antibiotic therapy would 
be appropriate.[53-55]
These cut-offs should be used as a guide, and CRP values should not 
be utilised in isolation without a clinical examination. Of note, it is 
also possible that viral infections, including uncomplicated influenza, 
may present with CRP values >100 mg/L.[56,57]
It is also useful to use CRP to identify patients presenting with 
AECOPD who are most likely to benefit from antibiotics. In one 
study of AECOPD comparing amoxicillin/clavulanate with placebo, 
the best CRP cut-off for predicting clinical failure in the placebo arm 
was 40 mg/L, with an area under the curve of 0.732 (95% CI 0.614 - 
0.851)[42] (Fig. 8).
The practical implications and considerations for POCT CRP in 
the SA setting that warrant closer attention include:
• Validation/verification of the POCT CRP assay used (to confirm 
the performance specifications as specified by the manufacturer)
• The cost of acquiring the desktop analyser
• Running costs, including calibration, internal and external quality 
control, and maintenance
• Training (initially and continuously) on daily operation
• Instrument storage specifications, including temperature and 
humidity control, etc.
Detailed discussion of these aspects falls outside the scope of this 
article. It cannot be overemphasised that the results produced by a 
desktop analyser need to adhere to quality standards.
Conclusion
The consequences of ABR in terms of patient outcomes and 
economic impact are not a distant threat, but are being played out 
‘here and now’. In SA, increasing levels of MDR, XDR and PDR 
organisms have been spawned by rampant over-use and incorrect 
use of anti biotics.[1,58] As such, antibiotics should be seen as a 
precious resource and the prescribing physician, particularly the GP, 
the guardian of this resource.
AS requires a collaborative effort on the part of policymakers, 
healthcare providers, healthcare insurance companies and patients. 
Besides the urgent need for AS governance in primary care, 
including optimal process and outcome measures, a drastic 
behavioural change is required by both doctors and patients, with 
more emphasis on non-antibiotic treatment options, particularly 
in the outpatient setting. To achieve this, primary care physicians 
need to assess their patients’ clinical presentation carefully, attempt 
to follow simple frameworks for clinical decision-making regarding 
antibiotic use and, where applicable, make appropriate use of POCT 
testing of biomarkers and cultures in order to minimise diagnostic 
uncertainty.[59] Understanding their patients’ expectations, along 
with improved communication of ABR principles, education and 
empowerment, are key to reducing antibiotic use in the outpatient 
setting.
Without techniques to change behaviour, such as goal setting 
for GPs to reduce antibiotic prescriptions, provision of feedback 
to enable self-monitoring and action planning based on guidelines 
such as these to reduce diagnostic uncertainty, antibiotic prescribing 
rates will remain stagnant.[60] Furthermore, according to the so-called 
‘Pareto Principle’ or ‘Law of the Vital Few’ (derived from economic 
theory and implying that 80% of outcomes result from only 20% of 
potential causes), by focusing on a few vital interventions, one can 
have a significant impact on outcome with less effort.[61] From a 
community stewardship point of view, it implies that even if the focus 
is placed on the appropriate diagnosis of ARTIs alone, this would 
represent a major target, with effect sizes of sufficient magnitude 
to have the potential to reduce the incidence of ABR bacteria in the 
community.[11]
Disclaimer. This clinical practice article is not intended as a sole source 
of guidance in the management of patients with the conditions described. 
Rather, it is intended to assist clinicians in decision-making. It is not 
intended to replace clinical judgement or establish a protocol for the care 
of all patients with the conditions described. These recommendations may 
not provide the only appropriate approach to the management of patients 
with such conditions.
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